BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17616972)

  • 1. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    Falda M; Busca A; Baldi I; Mordini N; Bruno B; Allione B; Rambaldi A; Morello E; Narni F; Santarone S; Locatelli F; Bacigalupo A;
    Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
    Brammer JE; Stentz A; Gajewski J; Curtin P; Hayes-Lattin B; Kovacsovics T; Leis JF; Meyers G; Nemecek E; Subbiah N; Frires R; Palmbach G; Avraham GP; Slater S; Maziarz RT
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
    Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Sobecks RM; Dean R; Rybicki LA; Chan J; Theil KS; Macklis R; Andresen S; Kalaycio M; Pohlman B; Ferraro C; Cherni K; Sweetenham J; Copelan E; Bolwell BJ
    Bone Marrow Transplant; 2008 Dec; 42(11):715-22. PubMed ID: 18711346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
    Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
    Girmenia C; Raiola AM; Piciocchi A; Algarotti A; Stanzani M; Cudillo L; Pecoraro C; Guidi S; Iori AP; Montante B; Chiusolo P; Lanino E; Carella AM; Zucchetti E; Bruno B; Irrera G; Patriarca F; Baronciani D; Musso M; Prete A; Risitano AM; Russo D; Mordini N; Pastore D; Vacca A; Onida F; Falcioni S; Pisapia G; Milone G; Vallisa D; Olivieri A; Bonini A; Castagnola E; Sica S; Majolino I; Bosi A; Busca A; Arcese W; Bandini G; Bacigalupo A; Rambaldi A; Locasciulli A
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):872-80. PubMed ID: 24631738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
    van der Straaten HM; Paquay MM; Tilanus MG; van Geloven N; Verdonck LF; Huisman C
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1231-6. PubMed ID: 21215810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
    Yanagisawa R; Nakazawa Y; Sakashita K; Tanaka M; Shikama N; Kamijo T; Shiohara M; Koike K
    Pediatr Transplant; 2009 Sep; 13(6):737-45. PubMed ID: 19207225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of unrelated donor umbilical cord blood transplantation for 30 adults with hematological malignancies.
    Kobayashi K; Maeda Y; Hara Y; Nishie-Kataoka M; Nishimori H; Sugiyama H; Namba N; Kubonishi S; Niiya M; Shinagawa K; Ikeda K; Tanimoto M
    Anticancer Res; 2009 May; 29(5):1763-70. PubMed ID: 19443401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
    Mickelson DM; Sproat L; Dean R; Sobecks R; Rybicki L; Kalaycio M; Pohlman B; Sweetenham J; Andresen S; Bolwell B; Copelan EA
    Bone Marrow Transplant; 2011 Jan; 46(1):84-9. PubMed ID: 20305699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
    Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H
    Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.